French-based pharmaceutical company Sanofi has received the US Food and Drug Administration (FDA) approval for Adlyxin (lixisenatide) injection to treat adult patients with type II diabetes.

Adlyxin is a once-daily, mealtime, Glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection that is used as an adjunct to diet and exercise in order to treat type II diabetes in adults, thereby improving their blood sugar (glucose) control.

Adlyxin is not insulin and not prescribed for use in place of long-acting insulin. The injectable drug should not be used on patients with type I diabetes or with diabetic ketoacidosis.

Sanofi global diabetes and cardiovascular business unit executive vice-president and head Peter Guenter said: “The approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people living with diabetes when trying to reach and maintain their individual blood glucose (HbA1c) targets.

"We are pleased with this approval as it offers us the opportunity to continue helping patients treated with basal insulin who remain uncontrolled."

“We are pleased with this approval as it offers us the opportunity to continue helping patients treated with basal insulin who remain uncontrolled.”

Adlyxin will be available for the patients within a disposable pre-filled pen in a single dose of 20mg, as well as a single dose of 10mg, which should be initiated by the patients once a day for two weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

After taking the medicine for a fortnight, the patients will have to increase the dosage to 20mg once daily on the fifteenth day.

Under the proprietary name Lyxumia, Adlyxin is approved in more than 60 countries and marketed in more than 40 nations.

Adlyxin can cause serious side effects including the inflammation of the pancreas (pancreatitis), which may be severe and can also lead to death.